Abeona Therapeutics (ABEO) Gains from Investment Securities (2016 - 2026)

Abeona Therapeutics' Gains from Investment Securities history runs 6 years deep, the most recent figure standing at -$5.4 million for Q1 2026.

• On a quarterly basis, Gains from Investment Securities rose 25.66% year-over-year to -$5.4 million in Q1 2026; TTM through Mar 2026 was -$4.3 million, a 82.01% increase from a year earlier, with the FY2025 full-year figure at -$6.1 million, down 913.11% from the prior year.
• Gains from Investment Securities eased to -$5.4 million in Q1 2026 per ABEO's latest filing, from -$1.5 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $17.3 million in Q1 2024 and bottomed at -$24.9 million in Q2 2024.
• The 5-year median for Gains from Investment Securities is -$2.3 million (2023), against an average of -$615176.5.
• Biggest YoY gain for Gains from Investment Securities was 1276.57% in 2024; the steepest drop was 388.87% in 2024.
• Year by year, Gains from Investment Securities stood at -$5.4 million in 2022, then surged by 178.51% to $4.2 million in 2023, then plunged by 260.17% to -$6.8 million in 2024, then surged by 77.54% to -$1.5 million in 2025, then slumped by 253.88% to -$5.4 million in 2026.
• Per Business Quant, the three latest ABEO Gains from Investment Securities figures stand at -$5.4 million (Q1 2026), -$1.5 million (Q4 2025), and -$2.8 million (Q3 2025).